Should large cell neuroendocrine lung carcinoma be classified and treated as a small cell lung cancer or with other large cell carcinomas?

Journal of Thoracic Oncology

Volumn 6, Issue 6, 2011, Pages 1050-1058

  Varlotto, John M ^a   Medford Davis, Laura Nyshel ^b   Recht, Abram ^b,c   Flickinger, John C ^d   Schaefer, Eric ^e   Zander, Dani S ^f   Decamp, Malcolm M ^g  

^a PENN STATE CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^e PENNSYLVANIA STATE UNIVERSITY   (United States)

^f PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^g NORTHWESTERN MEMORIAL HOSPITAL   (United States)

Author keywords

Large cell carcinoma; Large cell neuroendocrine carcinoma; Patient characteristics; Prognosis; Small cell carcinoma

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; FEMALE; HUMAN; LARGE CELL CARCINOMA; LUNG CARCINOMA; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE TUMOR; OVERALL SURVIVAL; PRIORITY JOURNAL;

EID: 79958077774     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318217b6f8     Document Type: Article

References (27)

1. Travis WD, Linnoila RI, Tsokos MG, et al. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma: an ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol 1991;15:529-553.
2. Travis WD, Rush W, Flieder DB, et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol 1998;22:934-944. (Pubitemid 28364493)
3. Travis WD, Brambilla E, Muller-Hermelink HK, et al. (Eds.), Pathology and Genetics of Tumors of Lung, Pleura, Thymus and Heart. Lyon: IARC Press, 2004. Pp. 37-38.
4. Chen LC, Travis WD, Krug LM. Pulmonary neuroendocrine tumors: what (little) do we know? J Natl Compr Canc Netw 2006;4:623-630. (Pubitemid 44265468)
5. Asamura H, Kameya T, Matsuno Y, et al. Neuroendocrine neoplasms of the lung: a prognostic spectrum. J Clin Oncol 2006;24:70-76. (Pubitemid 46630496)
6. Surveillance, Epidemiology, and End Results (SEER) Program Public-Use Data (1973-2003), National Cancer Institute, DCCPS, Surveillance Research Statistics Branch. Available at: http.//seer.cancer.gov/publicdata/. Accessed May 9, 2010.
7. Surveillance, Epidemiology and End Results (SEER) Program Web Site. Data Quality. Available at: http.//seer.cancer.gov/about/quality.html. Accessed May 9, 2010.
8. Faggiano A, Sabourin JC, Ducreux M, et al. Pulmonary and extrapulmonary poorly differentiated large cell neuroendocrine carcinomas: diagnostic and prognostic features. Cancer 2007;110:265-274. (Pubitemid 47121885)
9. Selvaggi G, Scagliotti GV. Histologic subtype in NSCLC: does it matter? Oncology 2009;23:1133-1140.
10. Iyoda A, Hiroshima K, Toyozaki T, et al. Clinical characterization of pulmonary large cell neuroendocrine carcinoma and large cell carcinoma with neuroendocrine morphology. Cancer 2001;91:1992-2000. (Pubitemid 32476362)
11. Jiang SX, Kameya T, Shoji M, et al. Large cell neuroendocrine carcinoma of the lung: a histologic and immunohistochemical study of 22 cases. Am J Surg Pathol 1998;22:526-537. (Pubitemid 28213738)
12. Takei H, Asamura H, Maeshima A, et al. Large cell neuroendocrine carcinoma of the lung: a clinicopathologic study of eighty-seven cases. J Thorac Cardiovasc Surg 2002;124:285-292. (Pubitemid 35025604)
13. Paci M, Cavazza A, Annessi V, et al. Large cell neuroendocrine carcinoma of the lung: a 10-year clinicopathologic retrospective study. Ann Thorac Surg 2004;77:1163-1167. (Pubitemid 38452339)
14. Battafarano RJ, Fernandez FG, Ritter J, et al. Large cell neuroendocrine carcinoma: an aggressive form of non-small cell lung cancer. J Thorac Cardiovasc Surg 2005;130:166-172. (Pubitemid 40941686)
15. Carvalho L. Reclassifying bronchial-pulmonary carcinoma: differentiating histological type in biopsies by immunohistochemistry. Rev Port Pneumol 2009;15:1101-1019.
16. Machevsky AM, Gal AA, Shah S, et al. Morphometry confirms the presence of considerable nuclear size overlap between "small cells" and "large cells" in high-grade pulmonary neuroendocrine neoplasms. Am J Clin Pathol 2001;116:466-472. (Pubitemid 34450278)
17. Douillard J, Rosell R, Delena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006;7:719-727. (Pubitemid 44283661)
18. Strauss GM, Herndon JE, Maddaus MA, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer. CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 2008;26:5043-5051.
19. Arriagada R, Dunant A, Pignon J-P, et al. Long-term results of the International Adjuvant Lung Cancer Trial evaluating adjuvant cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol 2010;28:35-42.
20. Butts CA, Ding K, Seymour L, et al. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small cell lung cancer: updated survival analysis of JBR-10. J Clin Oncol 2010;28:29-34.
21. Douillard JY, Tribodet H, Aubert D, et al. Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer: subgroup analysis of the lung adjuvant cisplatin evaluation. J Thorac Oncol 2010;5:220-228.
22. Fernandez FG, Battafarano RJ. Large-cell neuroendocrine carcinoma of the lung: an aggressive neuroendocrine lung cancer. Semin Thorac Cardiovasc Surg 2006;18:206-210. (Pubitemid 44914574)
23. Gollard R, Jhatakia S, Elliot M, et al. Large cell/neuroendocrine carcinoma. Lung Cancer 2010;69:13-18.
24. Davidoff AJ, Tang M, Seal B, et al. Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 2010;28:2191-2197.
25. Sartori G, Cavazza A, Sgambato A, et al. EGFR and K-Ras mutations along the spectrum of pulmonary epithelial tumors of the lung and elaborations of a combined clinicopathologic and molecular scoring system to predict clinical responsiveness to EGFR inhibitors. Am J Clinic Pathol 2009;131:478-489.
26. Langer CJ, Besse B, Gualberto A, et al. The evolving role of histology in the management of advanced non-small cell lung cancer. J Clin Oncol 2010;28:5311-5320.
27. Field RW, Smith BJ, Platz CE, et al. Lung cancer histologic type in the surveillance, epidemiology, and end results registry versus independent review. J Natl Cancer Inst 2004;96:1105-1107. (Pubitemid 39172413)